Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-one analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $266.21.
A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company reiterated an "outperform" rating on shares of Axsome Therapeutics in a research report on Tuesday, November 3rd. Morgan Stanley dropped their price target on Axsome Therapeutics from $249.00 to $223.00 and set an "equal weight" rating for the company in a research note on Friday, November 13th. Mizuho dropped their target price on shares of Axsome Therapeutics from $284.00 to $272.00 and set an "outperform" rating for the company in a report on Wednesday, November 4th. UBS Group cut their target price on shares of Axsome Therapeutics from $256.00 to $239.00 and set a "buy" rating on the stock in a research report on Tuesday, November 3rd. Finally, Robert W. Baird decreased their price objective on shares of Axsome Therapeutics from $246.00 to $220.00 and set an "outperform" rating for the company in a research report on Tuesday, November 3rd.
Get Our Latest Report on Axsome Therapeutics
Axsome Therapeutics Trading Down 4.7%
Shares of NASDAQ:AXSM opened at $129.36 on Friday. Axsome Therapeutics has a 12-month low of $123.00 and a 12-month high of $260.19. The stock has a market cap of $6.80 billion, a PE ratio of -42.27 and a beta of 0.86. The business has a 50 day moving average of $163.75 and a 200-day moving average of $195.47. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.38. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The company had revenue of $259.69 million during the quarter, compared to the consensus estimate of $249.19 million. During the same quarter last year, the firm earned ($0.94) earnings per share. The company's revenue was up 51.9% on a year-over-year basis. As a group, equities research analysts forecast that Axsome Therapeutics will post -2.27 earnings per share for the current year.
Insider Buying and Selling at Axsome Therapeutics
In other news, COO Mark Jacobson sold 10,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares of the company's stock, valued at $2,086,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 20.60% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in Axsome Therapeutics in the second quarter worth $759,695,000. First Trust Advisors LP increased its stake in Axsome Therapeutics by 1,230.2% in the first quarter. First Trust Advisors LP now owns 577,479 shares of the company's stock valued at $97,606,000 after acquiring an additional 534,066 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Axsome Therapeutics during the 2nd quarter valued at about $110,756,000. Bellevue Group AG lifted its position in Axsome Therapeutics by 9,112.7% in the 3rd quarter. Bellevue Group AG now owns 247,730 shares of the company's stock worth $45,679,000 after buying an additional 245,041 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in Axsome Therapeutics in the 2nd quarter worth approximately $55,171,000. Institutional investors own 81.49% of the company's stock.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.